GLOB Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Globant (GLOB)

Globant's Q2 2026 report showed revenue of roughly $614.4 million -- essentially flat year over year -- and full-year 2026 guidance was cut from slight growth to a slight decline, sending shares sharply lower and drawing analyst downgrades. Levi & Korsinsky is investigating potential securities law violations.

NEW YORK--(BUSINESS WIRE)--Shareholders of Globant (NYSE: GLOB) absorbed a sharp decline in the shares after the Company's Q2 2026 earnings release, which reported revenue of approximately $614.4 million and a reduced full-year 2026 revenue forecast. Investors who lost money on GLOB are encouraged to request a review of your GLOB losses now. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

The reported quarter came in below street consensus, and the guidance revision moved the full-year outlook from expected slight growth to a slight year-over-year decline. On February 26, 2026, Globant had guided FY2026 revenue of $2,460 million to $2,510 million, implying 0.2% to 2.2% year-over-year growth. On May 14, 2026, the Company raised the low end of that range and reaffirmed the midpoint at $2,462 million to $2,508 million. The reduction followed roughly three months later.

Analysts followed with downgrades and price-target cuts citing weaker near-term growth and pressure on the legacy time-and-materials business.

If you purchased Globant shares and suffered a loss, click here to submit your information. You may also contact Joseph E. Levi, Esq. via email at [e-mail] or by telephone at [phone].

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities class actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the GLOB Investigation

Q: Who is eligible to participate in the GLOB investigation? A: Investors who purchased GLOB stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether Globant made materially false or misleading statements regarding its full-year 2026 revenue outlook and near-term demand trends. When the Company reported approximately flat Q2 2026 revenue and reduced its full-year 2026 forecast to a slight year-over-year decline, the stock price declined sharply.

Q: When did Globant allegedly mislead investors? A: The investigation concerns statements made before the corrective disclosure that allegedly caused investors to purchase securities at inflated prices.

Q: What do GLOB investors need to do right now? A: Investors may gather brokerage records showing purchase dates, share quantities, and prices paid. Submit your information for a no-cost, no-obligation evaluation of your potential recovery. No immediate action is required to remain eligible to participate in the investigation.

Q: What documents do I need to participate? A: Brokerage statements or trade confirmations showing purchase dates, share quantities, prices paid, and any subsequent sale dates and prices.

Q: What if I already sold my GLOB shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought GLOB and sold at a loss may still participate in the investigation.

Q: What if my GLOB losses are small -- is it still worth contacting a lawyer? A: Yes. There is no minimum loss amount required to participate in the investigation.

Q: What does it cost me to participate? A: There is no upfront cost to submit your information and review whether you may be eligible to recover. Should you choose to participate in any resulting action, these matters are generally handled on a contingency basis, with any attorneys' fees and expenses subject to court approval.

Attorney Advertising. Prior results do not guarantee similar outcomes.